TNFSF11 and bone metastasis: Indeed, several large phase 3 trials have proven the benefit of BPs and of denosumab (a monoclonal antibody that neutralizes receptor activator of nuclear factor kappa-B ligand (RANKL)) by decreasing the morbidity associated with bone metastasis.